President Donald Trump on Thursday announced a deal with drugmaker Regeneron to lower the cost of its pharmaceutical products as part of the White House’s signature drug pricing initiative.
The deal involves Regeneron lowering the prices of all its current and future drugs on Medicaid, according to Trump. It also involves selling a cholesterol drug called Praluent for $225 on the White House’s discounted drug website TrumpRx, according to the agreement first outlined by NOTUS and confirmed in a White House fact sheet.
The deal comes as the Trump administration has been touting efforts to provide economic relief ahead of November’s midterm elections, with Americans saying high costs for health care, gas, groceries and other basic needs are straining their budgets.
It’s one of many so-called most-favored-nation deals the Trump administration has made with drug companies to bring U.S. pharmaceutical prices to the same level as other developed nations. Last July, Trump publicly sent letters to executives at 17 major pharmaceutical companies about the issue. Regeneron is the final one of those companies to strike a deal with his administration.
Speaking at the White House on Thursday to announce the deal, Trump touted the discounts on drugs and said, “It should be front page news.” He said voters in this November’s midterm elections should reward his party because of the agreements with drugmakers.
